Ruoyu Wang, Gozde N Gunesli, Vilde Eide Skingen, Kari-Anne Frikstad Valen, Heidi Lyng, Lawrence S Young, Nasir Rajpoot
{"title":"Deep learning for predicting prognostic consensus molecular subtypes in cervical cancer from histology images.","authors":"Ruoyu Wang, Gozde N Gunesli, Vilde Eide Skingen, Kari-Anne Frikstad Valen, Heidi Lyng, Lawrence S Young, Nasir Rajpoot","doi":"10.1038/s41698-024-00778-5","DOIUrl":null,"url":null,"abstract":"<p><p>Cervical cancer remains the fourth most common cancer among women worldwide. This study proposes an end-to-end deep learning framework to predict consensus molecular subtypes (CMS) in HPV-positive cervical squamous cell carcinoma (CSCC) from H&E-stained histology slides. Analysing three CSCC cohorts (n = 545), we show our Digital-CMS scores significantly stratify patients by both disease-specific (TCGA p = 0.0022, Oslo p = 0.0495) and disease-free (TCGA p = 0.0495, Oslo p = 0.0282) survival. In addition, our extensive tumour microenvironment analysis reveals differences between the two CMS subtypes, with CMS-C1 tumours exhibit increased lymphocyte presence, while CMS-C2 tumours show high nuclear pleomorphism, elevated neutrophil-to-lymphocyte ratio, and higher malignancy, correlating with poor prognosis. This study introduces a potentially clinically advantageous Digital-CMS score derived from digitised WSIs of routine H&E-stained tissue sections, offers new insights into TME differences impacting patient prognosis and potential therapeutic targets, and identifies histological patterns serving as potential surrogate markers of the CMS subtypes for clinical application.</p>","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"9 1","pages":"11"},"PeriodicalIF":6.8000,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724963/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Precision Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41698-024-00778-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Cervical cancer remains the fourth most common cancer among women worldwide. This study proposes an end-to-end deep learning framework to predict consensus molecular subtypes (CMS) in HPV-positive cervical squamous cell carcinoma (CSCC) from H&E-stained histology slides. Analysing three CSCC cohorts (n = 545), we show our Digital-CMS scores significantly stratify patients by both disease-specific (TCGA p = 0.0022, Oslo p = 0.0495) and disease-free (TCGA p = 0.0495, Oslo p = 0.0282) survival. In addition, our extensive tumour microenvironment analysis reveals differences between the two CMS subtypes, with CMS-C1 tumours exhibit increased lymphocyte presence, while CMS-C2 tumours show high nuclear pleomorphism, elevated neutrophil-to-lymphocyte ratio, and higher malignancy, correlating with poor prognosis. This study introduces a potentially clinically advantageous Digital-CMS score derived from digitised WSIs of routine H&E-stained tissue sections, offers new insights into TME differences impacting patient prognosis and potential therapeutic targets, and identifies histological patterns serving as potential surrogate markers of the CMS subtypes for clinical application.
子宫颈癌仍然是全世界妇女中第四大最常见的癌症。本研究提出了一个端到端的深度学习框架,用于从h&e染色的组织学切片中预测hpv阳性宫颈鳞状细胞癌(CSCC)的一致分子亚型(CMS)。通过分析三个CSCC队列(n = 545),我们发现我们的数字- cms评分根据疾病特异性(TCGA p = 0.0022, Oslo p = 0.0495)和无病(TCGA p = 0.0495, Oslo p = 0.0282)生存率对患者进行了显著分层。此外,我们广泛的肿瘤微环境分析揭示了两种CMS亚型之间的差异,其中CMS- c1肿瘤表现出淋巴细胞存在增加,而CMS- c2肿瘤表现出高核多型性,中性粒细胞与淋巴细胞比例升高,恶性程度更高,与预后不良相关。本研究引入了一种具有潜在临床优势的数字化CMS评分,该评分来源于常规h&e染色组织切片的数字化wsi,为TME差异影响患者预后和潜在治疗靶点提供了新的见解,并确定了可作为CMS亚型潜在替代标记物的组织学模式,用于临床应用。
期刊介绍:
Online-only and open access, npj Precision Oncology is an international, peer-reviewed journal dedicated to showcasing cutting-edge scientific research in all facets of precision oncology, spanning from fundamental science to translational applications and clinical medicine.